We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca, J&J Working to Reduce Clot Risk in Their COVID-19 Vaccines, While EMA Scrutinizes J&J Data on Guillain-Barré Risk
AstraZeneca, J&J Working to Reduce Clot Risk in Their COVID-19 Vaccines, While EMA Scrutinizes J&J Data on Guillain-Barré Risk
AstraZeneca and Johnson & Johnson are looking at modifying their COVID-19 vaccines to reduce the risk of blood clots, while the European Medicines Agency (EMA), following the lead of the FDA, is analyzing data on rare cases of the nerve disorder Guillain-Barré syndrome (GBS) reported among people who had the J&J vaccine.